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Background: An important issue in the transplantation of livers procured from cardiac death donors
(CDDs) concerns why some centres report equivalent outcomes and others report inferior outcomes in
transplantations using CDD organs compared with standard criteria donor (SCD) organs. Resolving this
discrepancy may increase the number of usable organs.
Objectives: This study aimed to test whether differences in cold ischaemic time (CIT) are critical during
CDD organ transplantation and whether such differences might explain the disparate outcomes.
Methods: Results of CDD liver transplants in our own centre were compared retrospectively with results
in a matched cohort of SCD liver recipients. Endpoints of primary non-function (PNF) and ischaemic
cholangiopathy (IC) were used because these outcomes are clearly associated with CDD organ use.
Results: In 22 CDD organ transplants, CIT was a strong predictor of PNF or IC (P = 0.021). Minimising
CIT in CDD organ transplants produced outcomes similar to those in a matched SCD organ transplant
cohort at our centre and in SCD organ transplant results nationally (1- and 3-year graft and patient survival
rates: 90.9% and 73.3% vs. 77.6% and 69.2% in CDD and SCD grafts, respectively. A review of the
published literature demonstrated that centres with higher CITs tend to have higher rates of PNF or IC
(correlation coefficient: 0.41).
Conclusions: These findings suggest that a targeted effort to minimise CIT might improve outcomes
and allow the safer use of CDD organs.
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Introduction
Livers procured from cardiac death donors (CDDs) account
for >5% of transplant volume in the USA.1 Although CDDs are
an important source of organs, the use of CDD livers is tem-
pered by a number of reports demonstrating worse outcomes
and an increased rate of ischaemic cholangiopathy (IC) com-
pared with standard criteria donor (SCD) livers in some
centres.2–14 Ischaemic cholangiopathy is a devastating complica-
tion that often results in graft loss and significant morbidity and
cost; this drives an argument that proposes that CDD liver trans-
plantation should be limited until better outcomes can be
achieved.10,13
Nonetheless, reports from other centres demonstrate equiva-
lent outcomes with CDD and SCD livers.15–17 These reports,
together with long waiting times and mortality on the liver trans-
plant waiting list provide strong counter-arguments for the con-
tinued use of CDD organs. Explaining these disparate results
might provide guidance to increase the number of CDD organs
used and improve outcomes.
To investigate whether centre-specific patterns of use explain
the conflicting reports, the question of whether minimising cold
ischaemic time (CIT) can improve outcomes after CDD liver
transplantation was addressed. Length of CIT was specifically
examined because this is a modifiable parameter that can be
adopted universally and is relatively easy to implement. In
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addition, this pre-study focus minimises potential problems that
might arise in a statistical analysis that examines a large number of
risk factors for a particular outcome.
The occurrence of primary non-function (PNF) or IC was
chosen as the outcome measure that would best reflect an unsat-
isfactory liver. This outcome, and patient and graft survival, were
addressed in three ways. First, CIT was assessed in our programme
and correlated with outcomes in transplants using CDD organs.
Next, outcomes of transplants in which aggressive attempts were
made to limit CIT were compared between CDD grafts and a
matched cohort of SCD grafts. Finally, an analysis was undertaken
of all the published literature on outcomes after CDD organ trans-
plants for which relevant data were available.
Materials and methods
General considerations
The programme at our institution pursues a policy of CIT mini-
misation when using CDD livers; two teams are used to accom-
plish this. When the donor team determines that the liver is
useable, the recipient team begins the hepatectomy. Consistent
with published guidelines, livers are generally not used if the time
between extubation of the donor and flush is >30 min, or the time
between profound hypotension (systolic blood pressure [SBP]
<50 mmHg) in the donor and flush is >15 min.18,19
Definitions and endpoints
The relevant endpoint was PNF or IC. For a diagnosis of IC,
patients needed to have abnormal liver function tests and diffuse
intrahepatic strictures on either endoscopic retrograde cholang-
iography or percutaneous transhepatic cholangiography. This
endpoint was chosen to reflect a relevant clinical outcome indi-
cating significant organ damage around the time of procurement.
Time to death in CDD livers was defined as minutes from extu-
bation until declaration of death in the donor. Donor total warm
ischaemia time was defined as minutes elapsed from extubation to
initiation of cold perfusion, which includes phase I (withdrawal)
and phase II (circulatory arrest). Cold ischaemia time was defined
as hours elapsed from aortic perfusion in the donor to revascu-
larisation of the portal vein in the recipient.
Single-centre retrospective review
A single-centre retrospective review was performed to determine
whether CIT correlated with subsequent graft function in 22
patients in whom CDD liver transplants were performed between
June 2004 and December 2009 at the Beth Israel Deaconess
Medical Center. Approval was obtained from the institutional
review board (IRB).
Matched cohort study
Data for a matched group of 22 SCD organ transplant patients
were assembled after obtaining approval from the IRB to deter-
mine whether CDD organ transplant outcomes were inferior to
those in SCD grafts. As recipient cancer is not associated with PNF
or IC, laboratory Model for End-stage Liver Disease (MELD)
scores were used. The matched group was constructed as follows:
each CDD organ recipient was paired with the SCD organ recipi-
ent whose surgery was carried out closest in time and whose age
was within 5 years (older or younger), MELD score was within 5
points (higher or lower), and graft donor was of similar age. These
were chosen as the most relevant parameters consistent with
donor risk index and recipient outcome data.20
Literature analysis
To establish the effects of CIT on CDD organ transplant outcomes
reported in the world literature, all papers identified by a PubMed
search using the terms ‘DCD’ [donors after cardiac death], ‘liver’
and ‘transplant’ were reviewed. This search identified nine
primary research papers that included interpretable outcome
data, including rates of IC and PNF, as well as unambiguous
information on CIT.
Donors
The New England Organ Bank (NEOB) maintains a prospectively
collected database of all consented cardiac death organ donors.
The project was approved by the medical director and the Clinical
Policy Board in accordance with the NEOB’s research policy. All
CDD organ recoveries occurred in patients extubated under con-
trolled conditions after the decision was made to withdraw
support (Maastricht Classification III). Withdrawal of support
occurred in accordance with individual hospital policy, which
governed comfort measures and heparin administration. Data on
CDD age, gender, height, weight, co-morbidities, terminal liver
function tests, cause of death and biopsy results were collected, as
were vital signs in the period between consent and asystole. These
included time to death, oxygen saturations, blood pressure and
heart rate. After withdrawal of care, patients were monitored by
continuous electrocardiogram, blood pressure cuff, finger pulse
oximetry and physical examination. Typically, vital parameters
were recorded every 1–5 min. In all cases, death was defined as the
irreversible cessation of cardiopulmonary activity as evidenced by
5 min of asystole documented on a rhythm strip and absence of
spontaneous respirations according to the Uniform Declaration of
Death Act (reviewed by Dubois21). Death was pronounced by a
doctor not associated with the transplant team. Livers were pre-
served in University of Wisconsin solution.
Recipients
Information on recipient outcomes was gathered after obtaining
permission from the Beth Israel Deaconess Medical Center IRB.
All recipient data were collected from prospectively maintained
databases and included age, gender, ethnic origin, indication for
transplantation, co-morbidities, and post-transplantation vari-
ables as outlined above. It was policy to avoid performing trans-
plants in recipients who would be at risk for a difficult or long
hepatectomy (e.g. patients with prior surgery or portal vein
thrombosis) or long organ travel time (e.g. with out-of-region
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CDD organs) in order to minimise ischaemia times when the
allocation match run permitted. All patients received essentially
the same three-drug immunosuppression using tacrolimus or
cyclosporine, mycophenolate mofetil and steroids. A minority
were converted to rapamycin from prograf at least 1 month after
transplantation.
Statistical methods
Continuous variables are presented as mean  standard devia-
tion; categorical values are presented as percentages. Comparisons
between categorical variables were made with the chi-squared test.
Comparisons between continuous variables were made with the
two-tailed Student’s t-test. P-values of <0.05 were considered to
indicate statistical significance. The correlation coefficient was cal-
culated using Pearson’s formula.
Results
CDD and recipient characteristics and outcomes
Donor and recipient characteristics are summarised in Table 1.
Donors tended to be young, with an average age of 35 years,
mostly male (64%) and non-obese. Common causes of death
included head trauma and stroke. Cold times were generally short
(<6 h) and donors expired quickly after extubation. Times
between extubation or profound haemodynamic instability and
flush were similarly short, consistent with CDD organ practice at
our institution. All CDDs were extubated and death declared after
5 min of cardiac standstill by a doctor not associated with the
recovery team. Hence, all donors were extubated. All developed
profound hypotension (SBP < 50 mmHg) prior to asystolic arrest.
Recipients had an average age of 54 years and most were men
(72%). In 55%, hepatocellular carcinoma (HCC) was the primary
diagnosis; other common diagnoses included hepatitis C and
alcohol abuse. Laboratory MELD scores averaged 18.1, reflecting
the high percentage of patients with exception points for HCC.
Average follow-up was 35 months. Patient and graft survival
was 90.9% at 1 year and 73.3% at 3 years.
Parameters that affect outcomes after CDD
organ transplantation
To determine whether CIT was a risk factor for the development
of IC or PNF, a composite endpoint incorporating both out-
comes was chosen. Results are provided in Table 2. This com-
posite outcome was reported in five of 22 patients and included
three cases of IC and two of PNF. Of the three patients with IC,
one is alive and on the transplant waiting list 5 years after trans-
plant and the other two died at 13 months and 3 years after
transplant. Body mass index (BMI) was similar in patients who
reached the composite endpoint and those who did not. Donor
age and MELD score were higher in the poor outcome group,
but these differences did not reach statistical significance. By
contrast, the poor outcome group had longer CIT (P = 0.021),
longer time from extubation to flush (P = 0.027) and longer
time of profound hypotension (P = 0.043) compared with the
good outcome group.
Table 1 Characteristics of transplants using livers from cardiac
death donors
Donors (n = 22)
Age, years, mean  SD 35.3  12.4
Gender, n (%)
Male 14 (64%)
Female 8 (36%)
Body mass index, mean  SD 23.4  5.5
Cause of death, n (%)
Head trauma 6 (27%)
Stroke 8 (36%)
Drug overdose 2 (9%)
Cold time, h, mean  SD 5.9  2.0
Time from asystole to flush, min, mean  SD 8.0  2.8
Time from SBP < 50 mmHg to flush, min, mean  SD 13.9  6.7
Time from extubation to flush, min, mean  SD 24.0  7.1
Recipients (n = 22)
Age, years, mean  SD 54.4  7.5
Gender, n (%)
Male 16 (72%)
Female 6 (27%)
Cause of disease, n (%)
Idiopathic 1 (5%)
Hepatitis C virus 15 (68%)
Alcohol-related 5 (23%)
Hepatoma 12 (55%)
Laboratory MELD score, mean  SD 18.1  7.6
SD, standard deviation; SBP, systolic blood pressure; MELD,
Model for End-stage Liver Disease
Table 2 Comparison of groups with and without primary non-function (PNF) or ischaemic cholangiopathy (IC)
Endpoint Patients,
n
Age, years,
mean  SD
Donor BMI,
mean  SD
Cold time, h,
mean  SD
Extubation to flush,
min, mean  SD
SBP < 50 mmHg to
flush, min, mean  SD
MELD score,
mean  SD
PNF/IC (+) 5 43  4.1 23.4  4.5 7.72  2.6 30.2  9.0 18.8  8.2 22.6  5.7
PNF/IC (-) 17 32.6  13.0 23.3  2.4 5.4  2.9 22.1  5.1 12.4  8.5 17.0  7.4
P-value 0.112 NS 0.021 0.027 0.043 0.12
SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; MELD, Model for End-stage Liver Disease; NS, not significant
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Outcomes in a matched cohort of SCD liver recipients
To further evaluate outcomes in CDD liver transplants, a matched
cohort of non-CDD organ recipients was created (Table 3). Donor
factors compared between groups included age, BMI, gender and
trauma as the cause of death. There were no significant differences
between the groups in these parameters except that trauma was a
more common cause of death in CDDs (32% vs. 9%). Recipient
age and disease processes were also similar between the groups.
There were no statistically significant differences between the
groups in 1- or 3-year patient or graft survival rates. To determine
whether CDD organ use affected hospital costs, we examined
average length of stay (LoS) and number of readmissions in the
first year. Recipients of CDD organs had a shorter average stay
than SCD organ recipients (13.3 days vs. 19.0 days), although this
did not reach statistical significance (P = 0.14). Numbers of read-
missions did not vary between CDD and SCD organ recipients.
Summary of CIT and outcomes across the literature
To evaluate the entire international experience in CDD liver trans-
plantation, the nine publications reporting outcomes and cold
time data in such transplants were examined.12,13,15,16,22–25 These are
presented in Table 4. Sample sizes ranged from 13 to 141 patients.
The relevant endpoint of PNF or IC occurred in 0–55% of
patients. Cold ischaemia time varied between 295 min and
657 min.
Outcomes after CDD organ transplants correlate
with CIT
To determine if disparate outcomes reported by different centres
could be explained by CIT, IC and PNF were plotted against CIT
(correlation coefficient: 0.41) (Fig. 1).
Discussion
Our analysis offers three major findings.
1 Cold ischaemia time is a risk factor for poor outcomes after
CDD liver transplantation in our centre.
2 Matched cohort analysis demonstrates that outcomes in our
centre, which follows an aggressive policy to minimise CIT, are
equal between CDD and SCD organ transplantations.
3 In the published literature, CIT correlates with outcomes.
These findings strongly suggest that increased CIT is a causative
factor in poor outcomes after CDD liver transplantation. This is
an important result as it suggests that a policy to minimise CIT
can improve outcomes.
One-year patient survival after CDD liver transplantation
appears better than after SCD organ transplantation, although
this difference did not reach statistical significance. This finding is
almost certainly the result of donor selection, which we believe is
critically important in CDD liver transplantation.
Table 3 Donor and recipient characteristics and outcomes in matched cohorts of patients transplanted with cardiac death donor (CDD) and
standard criteria donor (SCD) organs, respectively
CDD organs SCD organs P-value
Transplant cases, n 22 22
Donor characteristics
Donor age, years, mean  SD 35.3  7.7 38.9  12.4 NS
Trauma as cause of death, % 32% 9%
Body mass index, mean  SD 23.6  5.4 24.7  5.1 NS
Donor male gender, % 55% 59%
Recipient characteristics
Age, years, mean  SD 56.2  7.5 56.4  6.1 NS
Disease process, n (%)
Alcohol-related 5 (23%) 6 (27%)
Hepatitis C virus 11 (50%) 14 (64%)
Malignancy 2 (9%) 1 (5%)
Unknown/other 4 (18%) 1 (5%)
MELD score, mean  SD 18.1  7.7 17.8  6.9 NS
Outcomes
PNF or IC, n (%) 5 (23%) 3 (14%) NS
1-year survival, 90.9% 77.6% 0.24
3-year survival 73.3% 69.2% NS
Length of stay, days, mean  SD 13.3  9.5 19  14.5 0.12
Readmissions in the first year, mean 3.5 3.5 NS
SD, standard deviation; MELD, Model for End-stage Liver Disease; PNF, primary non-function; IC, ischaemic cholangiopathy
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The correlation of CIT with poor outcomes after CDD trans-
plantation is not new. Chan and colleagues found an increased
risk for IC when CIT exceeded 9 h, and de Vera et al. found CIT of
8 h to be a significant risk factor.12,13 Additionally, Dubbeld and
colleagues found increased CIT correlated with worse outcomes.22
By contrast, other groups15–17,23 have demonstrated similar out-
comes in SCD and CDD organ transplantation. The significance
of our findings places all of these reports into a larger context that
potentially explains these disparate results on the basis of overall
CIT at a centre, which is a modifiable factor.
These findings have important clinical relevance. There is con-
siderable belief in the transplant community that CDD livers are
inferior to SCD organs. A consensus statement from the American
Society of Transplant Surgeons (ASTS) states that CDD outcomes
are less favourable20 and a recent editorial stated: ‘Fundamental
change is required to re-ignite interest in utilisation of DCD
[organs donated after cardiac death] for liver transplantation.
Until scientific or technologic advances are available, our current
strategies, techniques and policies are insufficient to maximise the
donor-pool potential.’11 Furthermore, costs and resource utilisa-
tion may be significantly higher in CDD liver transplantions,25,26
although, in our study, LoS and number of readmissions were
similar between the CDD and SCD organ transplant groups.
We propose that CDD organ transplant outcomes can be made
equal or to at least approach those of SCD organ transplants by
minimising CIT in the setting of careful donor and recipient
selection. We would further propose that centres put in place
procedures to foster this. One strategy would be to use two teams
in CDD organ transplants so that the recipient team can com-
mence surgery as soon as the donor team confirms that the liver is
useable. Our analysis suggests that predicted but unavoidable
delays, such as in a difficult hepatectomy, may represent a relative
contraindication for the use of a CDD liver. Other considerations
should include the presence of portal vein thrombosis or hepatic
arterial problems in recipients. These patients may need more
extensive vascular reconstruction. We do not believe these patients
should be excluded, but the extra operative time required should
be regarded as a factor in the decision for surgery.
This study is limited by a number of factors. Our data are
limited by small sample size and a low rate of complications,
which admit the possibility of type II statistical error. The
matched cohort data are also limited by sample size. Importantly,
we note that absolute outcomes in CDD organ transplants at our
centre, where 1-year graft survival is >90%, would be considered
acceptable regardless of the control group. Ideally, a multivariate
analysis is required, but this is not possible with this small sample.
Our analysis of the relevant literature is complicated by differ-
ences in practices at the various centres, including, but not limited
to, the choice of immunosuppressants, donor and recipient char-
acteristics, and surgeon and centre experience with the technique.
In addition, the correlation is not particularly strong. In particu-
lar, the study by Skaro et al. seems to be an outlier.25 These con-
founding variables cannot be controlled for in this type of study.
Table 4 Data reported in the published literature
Authors CIT, min Transplants, n PNF, n DBI, n Composite endpoint
Dubbeld et al.22 456 55 1 13 25%
Detry et al.23 451 58 2 7 15%
Grewal et al.16 378 108 4 9 12%
Pine et al.14 397 39 2 8 26%
de Vera et al.13 657 141 17 24 29%
Detry et al.15 295 13 0 0 0%
Chan et al.12 437 52 0 7 14%
Maheshwari et al.24 522 20 1 10 55%
Skaro et al.25 330 32 1 12 41%
Present study (BIDMC) data 385 22 2 3 23%
CIT, cold ischaemic time; PNF, primary non-function; DBI, diffuse biliary ischaemia; BIDMC, Beth Israel Deaconess Medical Center
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Figure 1 Analysis of the literature comparing primary non-function
(PNF) and ischaemic cholangiopathy (IC) with cold time when using
cardiac death donor livers for transplantation. There is a correlation
between the rate of significant complications and increasing cold
time (correlation coefficient: 0.41)
HPB 415
HPB 2011, 13, 411–416 © 2011 International Hepato-Pancreato-Biliary Association
Notwithstanding these limitations, we feel that the results pre-
sented, along with the well-known deterioration of organ physi-
ology during cold storage, present a compelling case for the
minimising of CIT in CDD organ transplantation. As a ran-
domised trial would not be ethical, this report presents an argu-
ment for the implementation of practices intended to keep CIT as
short as possible and always <7 h. Future research should focus on
investigating these short CIT transplants using a case–control
study design to determine whether outcomes in CDD and SCD
organ transplants can be made equivalent across centres.
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